Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) EBT Margin (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed EBT Margin for 9 consecutive years, with 22.48% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 222.0% year-over-year to 22.48%, compared with a TTM value of 15.56% through Dec 2025, up 537.0%, and an annual FY2024 reading of 10.46%, changed N/A over the prior year.
  • EBT Margin was 22.48% for Q4 2025 at Puma Biotechnology, up from 16.76% in the prior quarter.
  • Across five years, EBT Margin topped out at 25.16% in Q3 2024 and bottomed at 96.52% in Q3 2021.
  • Average EBT Margin over 5 years is 1.16%, with a median of 7.47% recorded in 2021.
  • The sharpest move saw EBT Margin crashed -6551bps in 2021, then soared 9593bps in 2022.
  • Year by year, EBT Margin stood at 7.83% in 2021, then grew by 6bps to 8.28% in 2022, then crashed by -265bps to 13.67% in 2023, then soared by 248bps to 20.26% in 2024, then grew by 11bps to 22.48% in 2025.
  • Business Quant data shows EBT Margin for PBYI at 22.48% in Q4 2025, 16.76% in Q3 2025, and 11.76% in Q2 2025.